Trial Profile
A Randomised, Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Dec 2011 Primary endpoint 'Objective-clinical-response-rate' has been met.
- 06 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
- 06 Dec 2011 Planned number of patients changed to 120, and actual to 53 as reported at the 34th Annual San Antonio Breast Cancer Symposium.